11/12/2013

The FDA granted fast-track designation to Alnylam Pharmaceuticals' patisiran, its lead candidate for transthyretin-mediated amyloidosis. The designation can reduce the review process from a year to eight months.

Full Story:
Boston Herald

Related Summaries